Crossmark

Treat-to-target fixed dose rituximab retreatment versus fixed interval retreatment with disease activity-guided rituximab dose optimisation for patients with rheumatoid arthritis: study protocol for a multicentre randomised controlled superiority trial focusing on long-term disease impact (RITUXERA)

Crossref DOI link: https://doi.org/10.1186/s13063-024-08542-7

Published Online: 2024-10-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

De Meyst, Elias https://orcid.org/0009-0002-7960-006X
Bertrand, Delphine

Joly, Johan

Doumen, Michaël

Marchal, Anja

Thelissen, Marc

Neerinckx, Barbara

Westhovens, René

Verschueren, Patrick
License Information

Text and Data Mining valid from 2024-10-15

Version of Record valid from 2024-10-15
More Information

Article History

Received: 10 June 2024

Accepted: 8 October 2024

First Online: 15 October 2024

Declarations

:

: The RITUXERA trial was approved by an independent ethics committee via the Clinical Trials Information System (CTIS) procedure of the European Medicines Agency (reference 2023-506638-59-01). All study participants will give written informed consent before study participation.

: Not applicable.

: Elias De Meyst and Michaël Doumen received a grant from Research Foundation – Flanders (FWO). All other authors have no conflict of interest to declare.

Document is current

Any future updates will be listed below